Market Insights: Global Chordoma Disease Growth

According to FutureWise analysis the Chordoma Disease Market in 2025 is US$ 4.71 billion, and is expected to reach US$ 14.39 billion by 2033 at a CAGR of 14.98%. The rise in chordoma cases is largely due to increased awareness and earlier diagnoses of rare cancers. Advances in molecular biology and targeted therapies, along with emerging treatments like immunotherapy and precision medicine, offer new hope for patients. Additionally, rising investments in rare disease research and clinical trials are expected to accelerate market development.

Chordoma is a rare and slowly growing malignant tumor that originates from remnants of the embryonic notochord found along the axial skeleton. This tumor has an annual incidence of approximately 1 case per million people, translating to around 300 new cases in the United States each year. It accounts for less than 1% of all primary bone tumors and 1–4% of malignant bone neoplasms. Chordomas primarily affect adults, with a peak incidence occurring between the ages of 50 and 60, and they show a male predominance of about 2:1. These tumors can be classified based on their location: sacrococcygeal (50% of cases), spheno-occipital (35%), and mobile spine (15%). Pediatric cases, which constitute less than 5% of all chordomas, are generally found in the cranial region and tend to be more aggressive.

Histological examination of chordomas reveals unique physaliphorous (bubble-bearing) cells that contain vacuolated cytoplasm within a myxoid matrix. These tumors typically stain positive for certain markers including brachyury (T gene, located at 6q27), cytokeratins, S100, and epithelial membrane antigen (EMA). The duplication of the T gene is a key characteristic that helps differentiate chordomas from similar tumors like chondrosarcomas. Chordomas can be further categorized into subtypes: conventional (the most common), chondroid (which has a hyaline matrix and a better prognosis), and dedifferentiated (high-grade with poor survival rates, making up less than 5%).

Clinically, chordomas manifest through symptoms caused by mass effect. Sacral tumors can lead to bowel and bladder dysfunction or sciatica, while clival tumors may result in cranial neuropathies, including diplopia and dysphagia, or issues related to pituitary function. Imaging studies, particularly MRI, typically show T2-hyperintense, lobulated midline masses accompanied by bone destruction and soft-tissue extension. A definitive diagnosis is made through biopsy, with confirmation of the tumor's origin achieved through brachyury immunohistochemistry.

FutureWise Market Research has published a report that provides an insightful analysis of Chordoma Disease Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=10843&type=requestsample

Chordoma Disease Market Segmentation:

By Diagnosis

• Blood Tests
• Imaging
  • Magnetic Resonance Imaging (MRI)
  • Xray
  • Positron Emission Tomography (PET) Scanning
  • Computed Tomography (CT) Scan
  • Bone Scan
• Biopsy
• Others

By Treatment

• Chemotherapy
  • Doxorubicin
  • Methotrexate
  • Others
• Cryosurgery
• Radiosurgery
• Targeted Therapy
  • Bevacizumab
  • Erlotinib
  • Others
• Radiation Therapy
  • Surgical Treatments
    • Radical Resections
    • Spinal Chordoma
    • Sacral Chordoma
    • Skull Base Chordoma
  • Others
• Others

By End User

• Hospital Pharmacies
• Clinics
• Cancer Care Centers
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Afric

Competitive Landscape in Chordoma Disease Market:

• AstraZeneca plc
• Actavis plc
• Celgene Corporation
• F. Hoffmann-La Roche AG
• Novartis International AG
• Pfizer, Inc.
• Bayer AG
• Amgen, Inc.
• Bristol-Myers Squibb and Company
• Eli Lilly and Company
• GlaxoSmithKline plc
• Sanofi S.A

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10843&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Chordoma Disease Market By Diagnosis, By Treatment, By End User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

Article source: https://article-realm.com/article/Health-Fitness/78558-Market-Insights-Global-Chordoma-Disease-Growth.html